Cancer and treatment distress psychometric evaluation over time: A BMT CTN 0902 secondary analysis

Karen L. Syrjala, Steven K. Sutton, Heather S.L. Jim, Jennifer M. Knight, William A. Wood, Stephanie J. Lee, Paul B. Jacobsen, Muneer H. Abidi, Jean C. Yi

Research output: Contribution to journalArticle

  • 5 Citations

Abstract

BACKGROUND: Routine monitoring of cancer-related distress is recognized as essential to quality care and mandated by a major accrediting organization. However, to the authors' knowledge, few cancer-specific measures have been developed to date to assess the multiple cancer-related factors contributing to this distress. In the current study, the authors examined the psychometric properties of the Cancer and Treatment Distress (CTXD) measure over time in hematopoietic cell transplantation (HCT) recipients. METHODS: As a secondary analysis of a multicenter randomized controlled clinical trial, adult patients undergoing autologous or allogeneic HCT completed patient-reported outcomes including the CTXD and the Medical Outcomes Study Short Form-36 (SF-36) before transplantation and 100 days and 180 days after HCT. RESULTS: Across 21 transplantation centers, a total of 701 patients consented, underwent transplantation, and were included in the current analyses, 645 of whom were alive at 100 days and 618 of whom were alive at 180 days. Internal consistency reliability was found to be strong for the overall CTXD at the 3 time points: Cronbach alphas (α) were.94,.95, and.95, respectively. Subscale reliability met hypothesized levels of an α>.70 across time, with the lowest reliability noted for the Identity subscale at 180 days (α =.77). Correlations with the SF-36 Mental Health subscale were higher than with the Physical Functioning subscale at each time point, thereby supporting convergent and discriminant validity. Strong correlations of the pretransplantation CTXD with the posttransplantation CTXD and SF-36 Mental Health subscale supported predictive validity. CONCLUSIONS: The CTXD is reliable and valid as a measure of cancer distress both before and after HCT. It may be a useful tool for measuring dimensions of distress and for defining those patients requiring treatment for distress during and after transplantation. Cancer 2017;123:1416–1423.

LanguageEnglish (US)
Pages1416-1423
Number of pages8
JournalCancer
Volume123
Issue number8
DOIs
StatePublished - Apr 15 2017

Fingerprint

Psychometrics
Cell Transplantation
Transplantation
Neoplasms
Mental Health
Therapeutics
Quality of Health Care
trans-crotonin
Randomized Controlled Trials
Outcome Assessment (Health Care)
Organizations

Keywords

  • Cancer and Treatment Distress (CTXD)
  • cancer distress measure
  • distress
  • hematopoietic cell transplantation
  • psychometrics
  • reliability
  • validity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Syrjala, K. L., Sutton, S. K., Jim, H. S. L., Knight, J. M., Wood, W. A., Lee, S. J., ... Yi, J. C. (2017). Cancer and treatment distress psychometric evaluation over time: A BMT CTN 0902 secondary analysis. Cancer, 123(8), 1416-1423. DOI: 10.1002/cncr.30454

Cancer and treatment distress psychometric evaluation over time : A BMT CTN 0902 secondary analysis. / Syrjala, Karen L.; Sutton, Steven K.; Jim, Heather S.L.; Knight, Jennifer M.; Wood, William A.; Lee, Stephanie J.; Jacobsen, Paul B.; Abidi, Muneer H.; Yi, Jean C.

In: Cancer, Vol. 123, No. 8, 15.04.2017, p. 1416-1423.

Research output: Contribution to journalArticle

Syrjala, KL, Sutton, SK, Jim, HSL, Knight, JM, Wood, WA, Lee, SJ, Jacobsen, PB, Abidi, MH & Yi, JC 2017, 'Cancer and treatment distress psychometric evaluation over time: A BMT CTN 0902 secondary analysis' Cancer, vol. 123, no. 8, pp. 1416-1423. DOI: 10.1002/cncr.30454
Syrjala KL, Sutton SK, Jim HSL, Knight JM, Wood WA, Lee SJ et al. Cancer and treatment distress psychometric evaluation over time: A BMT CTN 0902 secondary analysis. Cancer. 2017 Apr 15;123(8):1416-1423. Available from, DOI: 10.1002/cncr.30454
Syrjala, Karen L. ; Sutton, Steven K. ; Jim, Heather S.L. ; Knight, Jennifer M. ; Wood, William A. ; Lee, Stephanie J. ; Jacobsen, Paul B. ; Abidi, Muneer H. ; Yi, Jean C./ Cancer and treatment distress psychometric evaluation over time : A BMT CTN 0902 secondary analysis. In: Cancer. 2017 ; Vol. 123, No. 8. pp. 1416-1423
@article{60f1d6782a4545af9135f1adaf30142c,
title = "Cancer and treatment distress psychometric evaluation over time: A BMT CTN 0902 secondary analysis",
abstract = "BACKGROUND: Routine monitoring of cancer-related distress is recognized as essential to quality care and mandated by a major accrediting organization. However, to the authors' knowledge, few cancer-specific measures have been developed to date to assess the multiple cancer-related factors contributing to this distress. In the current study, the authors examined the psychometric properties of the Cancer and Treatment Distress (CTXD) measure over time in hematopoietic cell transplantation (HCT) recipients. METHODS: As a secondary analysis of a multicenter randomized controlled clinical trial, adult patients undergoing autologous or allogeneic HCT completed patient-reported outcomes including the CTXD and the Medical Outcomes Study Short Form-36 (SF-36) before transplantation and 100 days and 180 days after HCT. RESULTS: Across 21 transplantation centers, a total of 701 patients consented, underwent transplantation, and were included in the current analyses, 645 of whom were alive at 100 days and 618 of whom were alive at 180 days. Internal consistency reliability was found to be strong for the overall CTXD at the 3 time points: Cronbach alphas (α) were.94,.95, and.95, respectively. Subscale reliability met hypothesized levels of an α>.70 across time, with the lowest reliability noted for the Identity subscale at 180 days (α =.77). Correlations with the SF-36 Mental Health subscale were higher than with the Physical Functioning subscale at each time point, thereby supporting convergent and discriminant validity. Strong correlations of the pretransplantation CTXD with the posttransplantation CTXD and SF-36 Mental Health subscale supported predictive validity. CONCLUSIONS: The CTXD is reliable and valid as a measure of cancer distress both before and after HCT. It may be a useful tool for measuring dimensions of distress and for defining those patients requiring treatment for distress during and after transplantation. Cancer 2017;123:1416–1423.",
keywords = "Cancer and Treatment Distress (CTXD), cancer distress measure, distress, hematopoietic cell transplantation, psychometrics, reliability, validity",
author = "Syrjala, {Karen L.} and Sutton, {Steven K.} and Jim, {Heather S.L.} and Knight, {Jennifer M.} and Wood, {William A.} and Lee, {Stephanie J.} and Jacobsen, {Paul B.} and Abidi, {Muneer H.} and Yi, {Jean C.}",
year = "2017",
month = "4",
day = "15",
doi = "10.1002/cncr.30454",
language = "English (US)",
volume = "123",
pages = "1416--1423",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Cancer and treatment distress psychometric evaluation over time

T2 - Cancer

AU - Syrjala,Karen L.

AU - Sutton,Steven K.

AU - Jim,Heather S.L.

AU - Knight,Jennifer M.

AU - Wood,William A.

AU - Lee,Stephanie J.

AU - Jacobsen,Paul B.

AU - Abidi,Muneer H.

AU - Yi,Jean C.

PY - 2017/4/15

Y1 - 2017/4/15

N2 - BACKGROUND: Routine monitoring of cancer-related distress is recognized as essential to quality care and mandated by a major accrediting organization. However, to the authors' knowledge, few cancer-specific measures have been developed to date to assess the multiple cancer-related factors contributing to this distress. In the current study, the authors examined the psychometric properties of the Cancer and Treatment Distress (CTXD) measure over time in hematopoietic cell transplantation (HCT) recipients. METHODS: As a secondary analysis of a multicenter randomized controlled clinical trial, adult patients undergoing autologous or allogeneic HCT completed patient-reported outcomes including the CTXD and the Medical Outcomes Study Short Form-36 (SF-36) before transplantation and 100 days and 180 days after HCT. RESULTS: Across 21 transplantation centers, a total of 701 patients consented, underwent transplantation, and were included in the current analyses, 645 of whom were alive at 100 days and 618 of whom were alive at 180 days. Internal consistency reliability was found to be strong for the overall CTXD at the 3 time points: Cronbach alphas (α) were.94,.95, and.95, respectively. Subscale reliability met hypothesized levels of an α>.70 across time, with the lowest reliability noted for the Identity subscale at 180 days (α =.77). Correlations with the SF-36 Mental Health subscale were higher than with the Physical Functioning subscale at each time point, thereby supporting convergent and discriminant validity. Strong correlations of the pretransplantation CTXD with the posttransplantation CTXD and SF-36 Mental Health subscale supported predictive validity. CONCLUSIONS: The CTXD is reliable and valid as a measure of cancer distress both before and after HCT. It may be a useful tool for measuring dimensions of distress and for defining those patients requiring treatment for distress during and after transplantation. Cancer 2017;123:1416–1423.

AB - BACKGROUND: Routine monitoring of cancer-related distress is recognized as essential to quality care and mandated by a major accrediting organization. However, to the authors' knowledge, few cancer-specific measures have been developed to date to assess the multiple cancer-related factors contributing to this distress. In the current study, the authors examined the psychometric properties of the Cancer and Treatment Distress (CTXD) measure over time in hematopoietic cell transplantation (HCT) recipients. METHODS: As a secondary analysis of a multicenter randomized controlled clinical trial, adult patients undergoing autologous or allogeneic HCT completed patient-reported outcomes including the CTXD and the Medical Outcomes Study Short Form-36 (SF-36) before transplantation and 100 days and 180 days after HCT. RESULTS: Across 21 transplantation centers, a total of 701 patients consented, underwent transplantation, and were included in the current analyses, 645 of whom were alive at 100 days and 618 of whom were alive at 180 days. Internal consistency reliability was found to be strong for the overall CTXD at the 3 time points: Cronbach alphas (α) were.94,.95, and.95, respectively. Subscale reliability met hypothesized levels of an α>.70 across time, with the lowest reliability noted for the Identity subscale at 180 days (α =.77). Correlations with the SF-36 Mental Health subscale were higher than with the Physical Functioning subscale at each time point, thereby supporting convergent and discriminant validity. Strong correlations of the pretransplantation CTXD with the posttransplantation CTXD and SF-36 Mental Health subscale supported predictive validity. CONCLUSIONS: The CTXD is reliable and valid as a measure of cancer distress both before and after HCT. It may be a useful tool for measuring dimensions of distress and for defining those patients requiring treatment for distress during and after transplantation. Cancer 2017;123:1416–1423.

KW - Cancer and Treatment Distress (CTXD)

KW - cancer distress measure

KW - distress

KW - hematopoietic cell transplantation

KW - psychometrics

KW - reliability

KW - validity

UR - http://www.scopus.com/inward/record.url?scp=85006106915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006106915&partnerID=8YFLogxK

U2 - 10.1002/cncr.30454

DO - 10.1002/cncr.30454

M3 - Article

VL - 123

SP - 1416

EP - 1423

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 8

ER -